PI3K–AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds

Yeqin Yuan; Huizhi Long; Ziwei Zhou; Yuting Fu; Binyuan Jiang

doi:10.3390/biom13010093

Biomolecules (Jan 2023)

PI3K–AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds

Yeqin Yuan,
Huizhi Long,
Ziwei Zhou,
Yuting Fu,
Binyuan Jiang

Affiliations

Yeqin Yuan: Medical Research Center, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha 410004, China
Huizhi Long: School of Pharmacy, Hengyang Medical School, University of South China, Hengyang 421001, China
Ziwei Zhou: School of Pharmacy, Hengyang Medical School, University of South China, Hengyang 421001, China
Yuting Fu: Medical Research Center, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha 410004, China
Binyuan Jiang: Medical Research Center, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha 410004, China

DOI: https://doi.org/10.3390/biom13010093
Journal volume & issue: Vol. 13, no. 1
p. 93

Abstract

Read online

Breast cancer is the most commonly diagnosed cancer in women. The high incidence of breast cancer, which is continuing to rise, makes treatment a significant challenge. The PI3K–AKT pathway and its downstream targets influence various cellular processes. In recent years, mounting evidence has shown that natural products and synthetic drugs targeting PI3K–AKT signaling have the potential to treat breast cancer. In this review, we discuss the role of the PI3K–AKT signaling pathway in the occurrence and development of breast cancer and highlight PI3K–AKT-targeting natural products and drugs in clinical trials for the treatment of breast cancer.

Published in Biomolecules

ISSN: 2218-273X (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Microbiology
Website: https://www.mdpi.com/journal/biomolecules

About the journal

Abstract

Keywords